14c-Tipranavir (BioDeep_00000838606)
代谢物信息卡片
14c-Tipranavir
化学式: C31H33F3N2O5S (602.2062164)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4
InChI: InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1/i25+2
描述信息
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yenju Chu, Chaolong Qin, Wanshan Feng, Charles Sheriston, Yu Jane Khor, Concepción Medrano-Padial, Birgit E Watson, Teddy Chan, Binhua Ling, Michael J Stocks, Peter M Fischer, Pavel Gershkovich. Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.
International journal of pharmaceutics.
2021 Jun; 602(?):120621. doi:
10.1016/j.ijpharm.2021.120621. [PMID: 33892057] - Purushothaman Indu, Marimuthu Ragavan Rameshkumar, Narasingam Arunagirinathan, Naif Abdullah Al-Dhabi, Mariadhas Valan Arasu, Savarimuthu Ignacimuthu. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Journal of infection and public health.
2020 Dec; 13(12):1856-1861. doi:
10.1016/j.jiph.2020.10.015. [PMID: 33168456] - Yogesh Kumar, Harvijay Singh, Chirag N Patel. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Journal of infection and public health.
2020 Sep; 13(9):1210-1223. doi:
10.1016/j.jiph.2020.06.016. [PMID: 32561274] - Asres Berhan, Yifru Berhan. Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
PloS one.
2013; 8(4):e60814. doi:
10.1371/journal.pone.0060814. [PMID: 23593314] - Clotilde Allavena, Philippe Flandre, Pascal Pugliese, Marc-Antoine Valantin, Isabelle Poizot-Martin, André Cabié, Hugues Melliez, Lise Cuzin, Claudine Duvivier, Pierre Dellamonica, François Raffi. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
Scandinavian journal of infectious diseases.
2012 Jan; 44(1):37-43. doi:
10.3109/00365548.2011.598870. [PMID: 21851330] - Lauriane Goldwirt, Joséphine Braun, Nathalie de Castro, Isabelle Charreau, Aurélie Barrail-Tran, Constance Delaugerre, François Raffi, Caroline Lascoux-Combe, Jean-Pierre Aboulker, Anne-Marie Taburet, Jean-Michel Molina. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Antimicrobial agents and chemotherapy.
2011 Jul; 55(7):3613-5. doi:
10.1128/aac.01827-10. [PMID: 21576452] - Jens J Kort, Stella Aslanyan, Joseph Scherer, John P Sabo, Veronika Kohlbrenner, Patrick Robinson. Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.
Current HIV research.
2011 Jun; 9(4):237-46. doi:
10.2174/157016211796320306. [PMID: 21671884] - K Weizsaecker, M Kurowski, B Hoffmeister, D Schürmann, C Feiterna-Sperling. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide.
International journal of STD & AIDS.
2011 May; 22(5):294-5. doi:
10.1258/ijsa.2009.009166. [PMID: 21571982] - John P Sabo, Xiuyu Julie Cong, Michael-Friedrich Kraft, Lacey Wallace, Mark A Castles, Stefan Mauss, Thomas R MacGregor. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
European journal of clinical pharmacology.
2011 Mar; 67(3):277-81. doi:
10.1007/s00228-010-0907-1. [PMID: 20963404] - José Moltó, Marta Valle, José Ramón Santos, Cristina Miranda, Samandhy Cedeño, Eugenia Negredo, Mercedes Yritia, Sebastián Videla, Bonaventura Clotet. Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir.
AIDS research and human retroviruses.
2010 Nov; 26(11):1191-6. doi:
10.1089/aid.2009.0304. [PMID: 20860529] - J B Dumond, M Vourvahis, N L Rezk, K B Patterson, H-C Tien, N White, S H Jennings, S O Choi, J Li, M J Wagner, N M La-Beck, M Drulak, J P Sabo, M A Castles, T R Macgregor, A D M Kashuba. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.
Clinical pharmacology and therapeutics.
2010 Jun; 87(6):735-42. doi:
10.1038/clpt.2009.253. [PMID: 20147896] - Feng Li, Laiyou Wang, Grace L Guo, Xiaochao Ma. Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice.
Drug metabolism and disposition: the biological fate of chemicals.
2010 May; 38(5):871-8. doi:
10.1124/dmd.109.030817. [PMID: 20103582] - Judit Morello, Sonia Rodríguez-Novoa, Francisco Blanco, Eugenia Vispo, Pablo Barreiro, Gema Gonzalez-Pardo, Inmaculada Jiménez-Nácher, Juan González-Lahoz, Vincent Soriano. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.
Therapeutic drug monitoring.
2010 Apr; 32(2):242-4. doi:
10.1097/ftd.0b013e3181d3f97f. [PMID: 20216112] - C Palladino, V Briz, M I González-Tomé, J A León Leal, M L Navarro, M I de José, J T Ramos, Ma Angeles Muñoz-Fernández. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
AIDS research and human retroviruses.
2010 Mar; 26(3):301-5. doi:
10.1089/aid.2009.0151. [PMID: 20334565] - Jaromir Mikl, Mark S Sulkowski, Yves Benhamou, Douglas Dieterich, Stanislas Pol, Jürgen Rockstroh, Patrick A Robinson, Mithun Ranga, Jerry O Stern. Hepatic profile analyses of tipranavir in Phase II and III clinical trials.
BMC infectious diseases.
2009 Dec; 9(?):203. doi:
10.1186/1471-2334-9-203. [PMID: 20003457] - R Douglas Bruce, Frederick L Altice, David E Moody, Shen-Nan Lin, Wenfang B Fang, John P Sabo, Jan M Wruck, Peter J Piliero, Carolyn Conner, Laurie Andrews, Gerald H Friedland. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Drug and alcohol dependence.
2009 Dec; 105(3):234-9. doi:
10.1016/j.drugalcdep.2009.07.007. [PMID: 19726139] - C J L la Porte, J P Sabo, L Béïque, D W Cameron. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
Antimicrobial agents and chemotherapy.
2009 Nov; 53(11):4840-4. doi:
10.1128/aac.00462-09. [PMID: 19721063] - P A Pham, C J L la Porte, L S Lee, R van Heeswijk, J P Sabo, M M Elgadi, P J Piliero, P Barditch-Crovo, E Fuchs, C Flexner, D W Cameron. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
Antimicrobial agents and chemotherapy.
2009 Oct; 53(10):4385-92. doi:
10.1128/aac.00449-09. [PMID: 19667285] - Judit Morello, Carmen De Mendoza, Vincent Soriano, Lourdes Anta, Gema González-Pardo, Angélica Corral, Francisco Blanco, Inmaculada Jiménez-Nácher, Juan González-Lahoz, Sonia Rodríguez-Novoa. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy.
2009 Oct; 53(10):4153-8. doi:
10.1128/aac.00041-09. [PMID: 19596874] - William D Hanley, Larissa A Wenning, Allison Moreau, James T Kost, Eric Mangin, Trisha Shamp, Julie A Stone, Keith M Gottesdiener, John A Wagner, Marian Iwamoto. Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
Antimicrobial agents and chemotherapy.
2009 Jul; 53(7):2752-5. doi:
10.1128/aac.01486-08. [PMID: 19398643] - Jane M Sayer, John M Louis. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Proteins.
2009 May; 75(3):556-68. doi:
10.1002/prot.22271. [PMID: 18951411] - Shirlynn Chen, Mayur S Dudhedia, Zeren Wang, Richard T Darrington, Toby Tamblyn, John A Smoliga, Paul-James Jones, Steven L Krill. Drug-excipient complexation in lipid based delivery systems: an investigation of the Tipranavir-1,3-dioctanolyglycerol complex.
Journal of pharmaceutical sciences.
2009 May; 98(5):1732-43. doi:
10.1002/jps.21542. [PMID: 18781647] - Sharon L Walmsley, Kathleen Squires, Laurence Weiss, Philippa Easterbrook, Anna Orani, Michael Kraft, Joseph Scherer. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men.
AIDS (London, England).
2009 Jan; 23(3):429-31. doi:
10.1097/qad.0b013e3283229f81. [PMID: 19114862] - Charles J L la Porte, John P Sabo, Mabrouk Elgadi, D William Cameron. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.
Antimicrobial agents and chemotherapy.
2009 Jan; 53(1):162-73. doi:
10.1128/aac.00534-08. [PMID: 19015362] - Susan Cox, Justine Southby, Otto Linet, Karie Tackwell, Marie Borin, Kim Perry. Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study.
Clinical drug investigation.
2009; 29(11):721-8. doi:
10.2165/11319890-000000000-00000. [PMID: 19813775] - Laure Elens, Sophie Veriter, Vincent Di Fazio, Roger Vanbinst, Daniel Boesmans, Pierre Wallemacq, Vincent Haufroid. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Clinical chemistry.
2009 Jan; 55(1):170-4. doi:
10.1373/clinchem.2008.108647. [PMID: 19028822] - Juan C Salazar, Pedro Cahn, Ram Yogev, Marinella Della Negra, Guido Castelli-Gattinara, Claudia Fortuny, Patrica M Flynn, Carlo Giaquinto, Ping K Ruan, M Elizabeth Smith, Jaromir Mikl, Ante Jelaska. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
AIDS (London, England).
2008 Sep; 22(14):1789-98. doi:
10.1097/qad.0b013e32830c481b. [PMID: 18753862] - Sharon L Walmsley, Christine Katlama, Adriano Lazzarin, Keikawus Arestéh, Gerald Pierone, Gary Blick, Margaret Johnson, Ulrich Meier, Thomas R MacGregor, Johnathan G Leith. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
Journal of acquired immune deficiency syndromes (1999).
2008 Apr; 47(4):429-40. doi:
10.1097/qai.0b013e318160a529. [PMID: 18176328] - Judit Morello, Pilar Garcia Gascó, Sonia Rodriguez-Novoa, Carmen de Mendoza, Francisco Blanco, Gema Gonzalez-Pardo, Beatriz Sanz, Inmaculada Jimenez-Nacher, Vincent Soriano. Association between tipranavir plasma levels and virological response in HIV-infected patients.
AIDS research and human retroviruses.
2008 Mar; 24(3):389-91. doi:
10.1089/aid.2007.0225. [PMID: 18373431] - Peter Langmann, W Heinz, H Klinker, D Schirmer, C Guhl, M Leyh, R Winzer. High performance liquid chromatographic method for the determination of HIV-1 protease inhibitor tipranavir in plasma of patients during highly active antiretroviral therapy.
European journal of medical research.
2008 Feb; 13(2):52-8. doi:
NULL. [PMID: 18424362] - Víctor Julián Moreno Cuerda, Rafael Rubio García, Montserrat Morales Conejo. [New therapeutic options in protracted HIV-infected patients with virological failure].
Medicina clinica.
2008 Jan; 130(2):66-70. doi:
10.1157/13115036. [PMID: 18221677] - François Raffi, Manuel Battegay, Stefano Rusconi, Milos Opravil, Gary Blick, Roy T Steigbigel, Michael Kraft, Dietmar Neubacher, John P Sabo. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
AIDS (London, England).
2007 Sep; 21(14):1977-80. doi:
10.1097/qad.0b013e3282ef8600. [PMID: 17721109] - Sreeraj Macha, Linzhi Chen, Stephen H Norris, Elsy Philip, Yanping Mao, Helga Silverstein, Craig Struble, Wendy Beers. Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats.
The Journal of pharmacy and pharmacology.
2007 Sep; 59(9):1223-33. doi:
10.1211/jpp.59.9.0006. [PMID: 17883893] - Martin Markowitz, Leonard N Slater, Robert Schwartz, Powel H Kazanjian, Bruce Hathaway, David Wheeler, Mitchell Goldman, Dietmar Neubacher, Douglas Mayers, Hernan Valdez, Scott McCallister. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
Journal of acquired immune deficiency syndromes (1999).
2007 Aug; 45(4):401-10. doi:
10.1097/qai.0b013e318074eff5. [PMID: 17554217] - Linzhi Chen, John P Sabo, Elsy Philip, Yanping Mao, Stephen H Norris, Thomas R MacGregor, Jan M Wruck, Sandra Garfinkel, Mark Castles, Amy Brinkman, Hernan Valdez. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
Antimicrobial agents and chemotherapy.
2007 Jul; 51(7):2436-44. doi:
10.1128/aac.01115-06. [PMID: 17485497] - Antonio D'Avolio, Mauro Sciandra, Marco Siccardi, Lorena Baietto, Daniel Gonzalez de Requena, Stefano Bonora, Giovanni Di Perri. A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2007 Apr; 848(2):374-8. doi:
10.1016/j.jchromb.2006.10.030. [PMID: 17092784] - Sun Ok Choi, Naser L Rezk, Angela D M Kashuba. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Journal of pharmaceutical and biomedical analysis.
2007 Mar; 43(4):1562-7. doi:
10.1016/j.jpba.2006.11.017. [PMID: 17236737] - Joseph C Gathe, Gerald Pierone, Peter Piliero, Keikawus Arasteh, Rafael Rubio, Richard G Lalonde, David Cooper, Adriano Lazzarin, Veronika M Kohlbrenner, Catherine Dohnanyi, John Sabo, Douglas Mayers. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
AIDS research and human retroviruses.
2007 Feb; 23(2):216-23. doi:
10.1089/aid.2006.0178. [PMID: 17263650] - Daniel González de Requena, Andrea Calcagno, Stefano Bonora, Laura Ladetto, Antonio D'Avolio, Mauro Sciandra, Marco Siccardi, Olivia Bargiacchi, Alessandro Sinicco, Giovanni Di Perri. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
AIDS (London, England).
2006 Oct; 20(15):1977-9. doi:
10.1097/01.aids.0000247121.19951.fa. [PMID: 16988521] - Kim Keil, Robin Difrancesco, Gene D Morse. Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array.
Therapeutic drug monitoring.
2006 Aug; 28(4):512-6. doi:
10.1097/00007691-200608000-00005. [PMID: 16885718] - Rolf W Sparidans, Frits Dost, Kristel M L Crommentuyn, Alwin D R Huitema, Jan H M Schellens, Jos H Beijnen. Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma.
Biomedical chromatography : BMC.
2006 Aug; 20(8):671-3. doi:
10.1002/bmc.667. [PMID: 16799929] - Frank J Piacenti. An update and review of antiretroviral therapy.
Pharmacotherapy.
2006 Aug; 26(8):1111-33. doi:
10.1592/phco.26.8.1111. [PMID: 16863488] - E Dailly, V Reliquet, C Victorri-Vigneau, F Raffi, P Jolliet. A simple high performance liquid chromatography assay for monitoring plasma concentrations of tipranavir in HIV infected patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2006 Mar; 832(2):317-20. doi:
10.1016/j.jchromb.2006.02.004. [PMID: 16497564] - S Colombo, A Béguin, C Marzolini, A Telenti, J Biollaz, L A Decosterd. Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2006 Feb; 832(1):138-43. doi:
10.1016/j.jchromb.2005.11.040. [PMID: 16359932] - Emmanuelle Giraud, Elisabeth Rey, Jean-Marc Tréluyer, Gérard Pons, Vincent Jullien. Quantification of tipranavir in human plasma by high-performance liquid chromatography with UV detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2006 Jan; 830(1):86-90. doi:
10.1016/j.jchromb.2005.10.024. [PMID: 16260190] - Jennifer R King, Edward P Acosta. Tipranavir: a novel nonpeptidic protease inhibitor of HIV.
Clinical pharmacokinetics.
2006; 45(7):665-82. doi:
10.2165/00003088-200645070-00003. [PMID: 16802849] - Zelalem Temesgen, Francesca Cainelli, Sandro Vento. Tipranavir.
Drugs of today (Barcelona, Spain : 1998).
2005 Nov; 41(11):711-20. doi:
10.1358/dot.2005.41.11.937960. [PMID: 16395412] - Vijayabhaskar Reddy Kandula, Homayoun Khanlou, Charles Farthing. Tipranavir: a novel second-generation nonpeptidic protease inhibitor.
Expert review of anti-infective therapy.
2005 Feb; 3(1):9-21. doi:
10.1586/14787210.3.1.9. [PMID: 15757454] - Katherine F Croom, Susan J Keam. Tipranavir: a ritonavir-boosted protease inhibitor.
Drugs.
2005; 65(12):1669-77; discussion 1678. doi:
10.2165/00003495-200565120-00005. [PMID: 16060700] - K M L Crommentuyn, H Rosing, M J X Hillebrand, A D R Huitema, J H Beijnen. Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2004 May; 804(2):359-67. doi:
10.1016/j.jchromb.2004.01.041. [PMID: 15081931] - Saurabh Mehandru, Martin Markowitz. Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.
Expert opinion on investigational drugs.
2003 Nov; 12(11):1821-8. doi:
10.1517/13543784.12.11.1821. [PMID: 14585057] - Patrick Yeni. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
Journal of acquired immune deficiency syndromes (1999).
2003 Sep; 34 Suppl 1(?):S91-4. doi:
10.1097/00126334-200309011-00014. [PMID: 14562864] - S Rusconi, S La Seta Catamancio, P Citterio, S Kurtagic, M Violin, C Balotta, M Moroni, M Galli, A d'Arminio-Monforte. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.
Antimicrobial agents and chemotherapy.
2000 May; 44(5):1328-32. doi:
10.1128/aac.44.5.1328-1332.2000. [PMID: 10770770] - S M Poppe, D E Slade, K T Chong, R R Hinshaw, P J Pagano, M Markowitz, D D Ho, H Mo, R R Gorman, T J Dueweke, S Thaisrivongs, W G Tarpley. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
Antimicrobial agents and chemotherapy.
1997 May; 41(5):1058-63. doi:
10.1128/aac.41.5.1058. [PMID: 9145869]